▲ BUY
8
/ 10
Conviction
$ Value
$30K
Shares
3,500
Price
$8
Filed
Nov 19
▶ Why this score? (8/10)
- ✓ Open market buy (+3)
- ✓ % of holdings >= 20% (+2)
- ✓ Cluster: 4 insiders buying (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Winton Matthew
Title
Chief Commercial and Business
CIK
0001971400
Roles
Officer
Transaction Details
Transaction Date
2025-11-17
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
13,500
Footnotes
Shares purchased in open-market transactions.
Filing Info
Winton Matthew's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-11 | CRVO | A | $0 |
| 2025-11-18 | CRVO | ▲ | $12K |
| 2025-11-17 | CRVO | ▲ | $30K |
| 2025-11-14 | CRVO | ▲ | $76K ★ |
| 2025-10-06 | CRVO | A | $0 |
| 2025-07-01 | INZY | U | $87K |
| 2025-07-01 | INZY | D | — |
| 2025-07-01 | INZY | D | — |
| 2025-06-25 | INZY | A | $11K |
Other Insiders at CRVO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
ALAM JOHN J
CEO & President
|
— | — | 2026-02-11 |
| Gregoire Sylvie | — | — | 2026-02-11 |
|
Blackburn Kelly
EVP, Clinical Development
|
— | — | 2026-02-11 |
|
ELDER WILLIAM ROBERT
CFO, GC & Secretary
|
— | — | 2026-02-11 |
|
De Rosch Mark
EVP, RA and GA and PgM
|
— | — | 2026-02-11 |
|
Winton Matthew
Chief Commercial and Business
|
— | — | 2026-02-11 |